floriparesort.com – 19 June 2026 | The FDA panel backs mRNA shot for the upcoming flu season, a decision that could potentially change the way we approach influenza vaccination. As the US health advisers debate a new kind of flu vaccine, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older.
The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacture than other types — something experts say might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses to match.
![WHO Chief Visits Ebola Zone [titlebase]: A Desperate Bid to Contain the Outbreak](https://www.floriparesort.com/wp-content/uploads/2026/05/who-chief-visits-ebola-zone-titlebase-a-desperate-bid-to-contain-the-outbreak-60x60.webp)
In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to those given another routinely used vaccine brand. Ahead of the meeting, FDA published a favorable review of that data and reported no safety concerns. The FDA panel backs mRNA shot, and this decision could be a significant step forward in the fight against influenza.
The VRBPAC panel’s vote will focus on the risk-benefit profile of mFlusiva for influenza prevention in adults aged 50 to 64 years, and in the 65-year-and-older population. The briefing document released on Tuesday identified no major deficiencies. The primary efficacy analysis demonstrated that mRNA-1010 (TIV) met all prespecified sequential success criteria—noninferiority, superiority, and super-superiority—relative to the standard-dose (SD) comparator.
![RFK Jr. Fires Health Task Force Heads [titlebase]: A Shocking Move Amidst Ongoing Health Care Debates](https://www.floriparesort.com/wp-content/uploads/2026/05/rfk-jr-fires-health-task-force-heads-titlebase-a-shocking-move-amidst-ongoing-health-care-debates-60x60.webp)
High-dose, recombinant, and adjuvanted flu vaccines are generally preferred for adults 65 and older. Following a Type A meeting, the FDA assigned a Prescription Drug User Fee Act goal date of August 5 for mRNA-1010. It’s for adults aged 50 and older. Moderna proposed a regulatory pathway based on age, seeking full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, along with a postmarketing requirement to conduct an additional study in older adults.
The FDA panel backs mRNA shot, and this decision is crucial for the future of flu vaccination. As the FDA panel backs mRNA shot, it is essential to consider the potential impact on the pharmaceutical industry and the fight against influenza. The FDA panel backs mRNA shot, and this decision could be a significant step forward in the fight against influenza.
![Vanessa Trump Diagnosed w/ breast cancer [titlebase]: Understanding the Disease and Its Implications](https://www.floriparesort.com/wp-content/uploads/2026/05/vanessa-trump-diagnosed-w-breast-cancer-titlebase-understanding-the-disease-and-its-implications-60x60.webp)
In conclusion, the FDA panel backs mRNA shot for the upcoming flu season, a decision that could potentially change the way we approach influenza vaccination. As the US health advisers debate a new kind of flu vaccine, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA panel backs mRNA shot, and this decision could be a significant step forward in the fight against influenza.